Research ArticleCARDIOVASCULAR
Trimetazidine, Administered at the Onset of Reperfusion, Ameliorates Myocardial Dysfunction and Injury by Activation of p38 Mitogen-Activated Protein Kinase and Akt Signaling
Mahmood Khan, Sarath Meduru, Mahmoud Mostafa, Saniya Khan, Kàlmàn Hideg and Periannan Kuppusamy
Journal of Pharmacology and Experimental Therapeutics May 2010, 333 (2) 421-429; DOI: https://doi.org/10.1124/jpet.109.165175
Mahmood Khan
Sarath Meduru
Mahmoud Mostafa
Saniya Khan
Kàlmàn Hideg
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleCARDIOVASCULAR
Trimetazidine, Administered at the Onset of Reperfusion, Ameliorates Myocardial Dysfunction and Injury by Activation of p38 Mitogen-Activated Protein Kinase and Akt Signaling
Mahmood Khan, Sarath Meduru, Mahmoud Mostafa, Saniya Khan, Kàlmàn Hideg and Periannan Kuppusamy
Journal of Pharmacology and Experimental Therapeutics May 1, 2010, 333 (2) 421-429; DOI: https://doi.org/10.1124/jpet.109.165175
Research ArticleCARDIOVASCULAR
Trimetazidine, Administered at the Onset of Reperfusion, Ameliorates Myocardial Dysfunction and Injury by Activation of p38 Mitogen-Activated Protein Kinase and Akt Signaling
Mahmood Khan, Sarath Meduru, Mahmoud Mostafa, Saniya Khan, Kàlmàn Hideg and Periannan Kuppusamy
Journal of Pharmacology and Experimental Therapeutics May 1, 2010, 333 (2) 421-429; DOI: https://doi.org/10.1124/jpet.109.165175
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement